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SCOPING REVIEW Open Access
The causal relationship between
neurocysticercosis infection and the
development of epilepsy - a systematic
review
Lucy B. Gripper and Susan C. Welburn*
Abstract
Background: Neurocysticercosis (NCC) is a parasitic infection of the human central nervous system, the most
common form of which involves infection of the brain parenchyma with the larval form of the Taenia solium
tapeworm. A causal relationship between such an NCC infection and the development of epilepsy in infected
individuals is acknowledged, in part supported by high levels of comorbidity in endemic countries worldwide.
Methods: This study undertook a systematic review and critical analysis of the NCC-epilepsy relationship with the
primary objective of quantifying the risk of developing epilepsy following NCC infection. A secondary aim was to
analyse the proportions of NCC-associated epilepsy within different populations. Significant emphasis was placed on
the importance of neuroimaging (CT or MRI) availability and use of clear guidelines for epilepsy diagnosis, in order to
avoid overestimations of prevalence rates of either condition; a limitation identified in several previous studies.
Results: A common odds ratio of 2.76 was identified from meta-analysis of case-control studies, indicating that an
individual infected with NCC has almost a three times higher risk of developing epilepsy than an uninfected individual.
Furthermore, meta-analysis of studies identified a common proportion of 31.54% of epilepsy cases associated with NCC
infection which suggests that amongst epileptic populations in at risk countries, approximately one-third may be
associated with NCC infection.
Conclusion: A significant finding was the lack of good clinical data to enable accurate determination of a causal
relationship. Even studies that were included had noticeable limitations, including a general lack of consistency in
diagnostics, and lack of accurate epidemiological data. This review highlights a need for consistency in research in this
field. In the absence of reliable estimates of its global burden, NCC will remain of low priority in the eyes of funding
agencies - a truly neglected disease.
Multilingual abstracts
Please see Additional file 1 for translations of the abstract
into the six official working languages of the United Nations.
Background
Neurocysticercosis (NCC) is the most common parasitic
disease of the human central nervous system (CNS) [1].
NCC results from ingestion of the eggs of the flatworm
Taenia solium (commonly referred to as the ‘pork tape-
worm’) [2]; the oncospheres hatch in the intestine, pene-
trate the intestinal wall and disseminate to several body
tissues, showing strong tropism to the CNS [3]. Once
established the living parasite may be referred to as a
‘cysticercus’ or ‘viable cyst.’ The cysticercus may remain
in such a state indefinitely, before an environmental trig-
ger, such as the overcoming of cyst evasion mechanisms
by the host immune system, initiates a degenerative
transitionary phase. Gradual calcification of the cyst then
occurs, until cyst evolution is terminated, whereby it
becomes a non-viable, fully calcified nodule [4]. Clinical
presentation of these infections are highly pleomorphic,
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due to the extensive variations in number, location and
evolutionary stage of the parasites, with a clinical
spectrum of severity that ranges from no discernible
symptoms, to rapid increases in intracranial pressure,
occasionally leading to death [5]. The absence of a
consistent syndrome is one of many factors that hinders
making an accurate NCC diagnosis.
NCC has a diverse array of clinical manifestations,
depending on a complex range of interconnecting fac-
tors, including the number and size of the cysticerci
present, their stage of development, and localisation
within the brain; this contributes to significant difficul-
ties in accurate diagnosis and staging of the disease [6].
The parasite load, dependent on both the size and num-
ber of cysticerci, is an important determinant of symp-
tomatology, with high loads associated with increased
risk of obstruction and corresponding rises in intra-
cranial pressure (ICP), as well as induction of significant
inflammatory responses [5]. In very severe cases, involv-
ing numerous cysts with associated inflammation, an en-
cephalitic state can occur with diffuse cerebral oedema;
such cases have a very poor prognosis [7].
Despite being considered as the most prevalent neuro-
parasitic disease worldwide [8], NCC remains on the
World Health Organization (WHO) list of neglected
tropical diseases, endemic in many developing countries
in poverty-stricken areas of the world such as Sub-
Saharan Africa and Latin America [8].
Transmission of NCC involves the contamination of
food or water with the eggs of T. solium, excreted in the
faeces of a human tapeworm carrier, meaning that NCC
propagation is enhanced by the inadequacy of both sani-
tation and access to clean drinking water, commonly
experienced in developing countries. Pigs are the only
other established intermediate host of T. solium and, like
humans, may develop cysticercosis infection from the
ingestion of food or water contaminated with human
faeces [4]; in many developing countries it is common
practice to allow pigs to roam freely, exacerbating trans-
mission by enabling the frequent ingestion of human
faecal matter. The tapeworm cannot reproduce without
a definitive human host, and pigs are unable to directly
transmit NCC, however ingestion of undercooked pork
contaminated with cysticerci can lead to the adult tape-
worm infection, or taeniasis, in humans, completing the
lifecycle and increasing parasite burden [1].
Despite efforts by organizations such as WHO to in-
crease public awareness of NCC and improved strategies
for the control of T. solium-related disease, reducing the
disease burden is impeded by a number of factors. The
biology of the tapeworm itself makes effective control
very difficult, as a single adult can produce a minimum
of 100 000 eggs in a day [9], which can become distrib-
uted in the environment within a large radius of the
primary infection [9]; this high biotic potential is a sig-
nificant factor in the epidemiological stability of the
taeniasis-cysticercosis complex [8]. Importantly, strongly
established surveillance programs are also lacking in
many endemic areas, leading to a limited amount of ac-
curate epidemiological data that is crucial in the assess-
ment of disease transmission and distribution [10]; a
greater quantity of such data is key for the development
of future control and eradication strategies.
The neurocysticercosis-epilepsy relationship
Clinical presentation of NCC acknowledges seizures as
the most common manifestation of the parenchymal
form of the disease, occurring in up to 90% of symptom-
atic patients [11]. In many cases, the presence of seizures
has been interpreted as being synonymous with epilepsy,
especially in individuals where seizures are recurrent. It
is not uncommon for seizures to be attributed to epi-
lepsy and for NCC to be proposed as ‘a leading cause of
epilepsy in the developing world’ [12].
The clear distinctions between epilepsy and seizures
have often been overlooked [13]. The International
League Against Epilepsy (ILAE) defines epilepsy as ‘two
or more unprovoked seizures occurring at least 24 h
apart’ [14]. While this is a seemingly clear definition, it
is difficult to apply to NCC cases, mainly due to the sig-
nificance placed on the ‘unprovoked’ nature of seizures.
Individuals infected with NCC may remain asymptom-
atic for prolonged periods, a phenomenon thought to
arise from a complex immune evasion response initiated
by viable cysts; this allows them to remain undetected in
the body for an indefinite timespan [7]. Development of
symptoms, including seizures, are often associated with
the overcoming of such mechanisms by the immune
response, leading to an acute inflammatory reaction
[15]; seizures presenting in this context could therefore
be considered as having direct provocation. This has led
to a spectrum of interpretations as to what constitutes
epilepsy as opposed to provoked acute symptomatic
seizures, potentially influenced by whether an individual
cyst is in the viable, degenerative or calcified state. In-
consistency of such definitions between studies is a
major contributor to the difficulties in forming conclu-
sions regarding the causal nature of NCC-associated
seizures or epilepsy.
While it is not disputed that there are high rates of
NCC-epilepsy comorbidity in certain developing coun-
tries [16], determining the existence, or non-existence,
of a causal relationship between epilepsy and NCC is far
more complex. Considering the nature of the interac-
tions that exist between these two conditions, a number
of hypotheses can be considered. Firstly, that NCC is a
direct cause of epilepsy. This theory would need to con-
sider the dispute over whether direct provocation by
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inflammation of, and structural damage to, the brain
parenchyma would actually constitute epilepsy versus
acute symptomatic seizures.
Secondly, that NCC is a component of the epileptogenic
pathway, contributing to the development of the disease,
but not acting directly as a causative factor [17]. NCC
could be considered an ‘initial precipitating injury’ (IPI)
for epilepsy, where NCC infection acts as a trigger for fu-
ture spontaneous recurrent seizures and the development
of an epileptogenic profile, but is not directly responsible
for these subsequent individual seizure events [18].
Thirdly that there is an indirect link between epilepsy
and NCC due to an independent factor, causing a mis-
leading association between the two conditions. Some
studies have shown high rates of familial aggregation of
NCC, indicating the presence of a genetic predisposition
to the disease that may also be linked to increased risk
of epilepsy [19].
Finally, that the high rates of comorbidity of NCC and
epilepsy are coincidental due to high concurrent preva-
lence rates of the two conditions, which occur independ-
ently from one another, in certain countries [20, 21].
The aim of this study was to undertake a systematic
review and critical analysis of the available literature on
the NCC-epilepsy relationship, with the primary object-
ive of determining the risk of developing epilepsy follow-
ing initial infection with NCC. A secondary objective
was to assess the relative proportions of NCC-associated
epilepsy in different populations. Analysis of the litera-
ture in this area also allowed for consideration of the
evidence for and against the four possible hypotheses de-
fining this relationship, to better clarify the mechanisms
determining comorbidity.
Methodology
Literature search
A systematic search of the literature was conducted
using a three-phase approach to efficiently restrict stud-
ies for analysis to those containing relevant, high quality
data, from a large initial volume of identified studies fol-
lowing the PRISMA guidelines [22]. Phase 1 comprised
an initial search for studies documenting the relationship
between NCC and epilepsy. Two databases, MEDLINE
and Embase, were searched using the Ovid search plat-
form. The following keywords were used in a compre-
hensive literature search: ‘epilepsy’, ‘seizures’, ‘Taenia
solium’, ‘cysticercus’, ‘cysticercosis’, ‘neurocysticercosis’ and
‘taeniasis’. Exclusion criteria were intended to limit stud-
ies to those that included original, relevant data specific-
ally regarding the prevalence or incidence of NCC and
epilepsy in defined populations. The following categories
of study were excluded: those lacking original data, for
example review papers and editorials; those reporting
animal data in isolation, with no human subjects; single
case reports or studies with very small population sizes
(fewer than 20 participants); those containing a lack of
appropriate frequency data regarding the association
between NCC and epilepsy and those reporting on
agents other than T. solium. The majority of studies
fulfilling these criteria were conducted in the 1990s or
later. A screen of a random sample of papers published
before 1990 was conducted and yielded no studies for
inclusion as they did not meet the criteria.
Phase 2: full text review
For inclusion for full text review, studies required to
have access to neuroimaging equipment, whether CT or
MRI, for the visual detection of cysts, to aid accurate
diagnosis of NCC. Autopsy studies, where cysts could
still be directly visualized and biopsied, were also in-
cluded. Commonly, immune-serological tests are used in
isolation for the clinical diagnosis of NCC, as these are
more practical in resource-poor developing countries
that are endemic for the disease [22], yet there are a
number of issues associated with such methods. The
enzyme-linked immune-electro-transfer blot (EITB)
assay, which uses targeted antigens to detect serum T.
solium antibodies, is one of the most widely used assays
for NCC diagnosis [2]; however, in endemic countries,
where environmental exposure to NCC is high, a signifi-
cant proportion of individuals from the general popula-
tion will test positive for antibodies despite not having
active NCC infection [23–25]. This can lead to overesti-
mation of NCC prevalence within study populations.
More recently, antigen-detecting ELISA assays have
been suggested as an improvement over the EITB, as the
detection of T. solium antigens instead of antibodies in-
dicates the presence of an established NCC infection, as
opposed to exposure only [26]. Serological results are
useful as a component of a diagnostic toolbox, but only
serve to strengthen a suspected diagnosis, interpreted in
a clinical context. Combining these results with neuro-
imaging data was expected to provide the most reliable
estimates for NCC prevalence.
Another important inclusion criterion was that methods
of epilepsy diagnosis had to meet a certain stand-
ard [14, 27]. Given the confusion regarding classifica-
tion of seizures, and distinction between seizures and
epilepsy, studies needed to provide clear definitions of
seizure activity in their subjects. Ideally symptoms
would be classified according to internationally accepted
guidelines, such as those provided by the International
League Against Epilepsy [28] (http://www.ilae.org), how-
ever as long as general classifications were clearly defined
this was not an absolute requirement. Diagnoses could
not be based solely on patient history without assessment
and confirmation by a qualified clinician, as patient expe-
riences in isolation could introduce an element of recall
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bias into the determination of proportions of people with
epilepsy (PWE).
Phase 3: data extraction
Prior to data extraction, study characteristics of included
papers for review and statistical analysis were assessed
and recorded in a Microsoft Excel spreadsheet. Aspects
of the studies considered included: year of publication;
country in which the study was conducted; the study
objective(s); study design e.g., cross-sectional; methods
for determining the study population e.g., selection of
cases versus controls in relevant studies; size and charac-
teristics of the study population; methods of epilepsy
diagnoses and methods used to make NCC diagnoses.
Studies were ordered according to design with case-
control studies separated from cohort and cross-sectional
studies, since these designs yielded different data types
that were used separately in statistical analyses. Data
concerning the frequency of NCC and epilepsy cases
respectively, within different populations, was extracted
and entered into standardized tables, adapted to each
study design.
Statistical analysis
Meta-analysis of case-control data was used to estimate
the risk of developing epilepsy following exposure to
NCC infection. MedCalc statistical software was used to
calculate odds ratios (ORs) for each set of study data,
with 95% confidence intervals (CIs) and P values to test
for statistical significance. The degree of heterogeneity
between studies was measured using the I2 index, which
assesses the total variability of results due to deviations
between studies [29]. A second meta-analysis was carried
out on prevalence data from cohort and cross-sectional
studies to assess the proportions of NCC-associated
epilepsy within different populations. As before, pro-
portions were calculated using MedCalc software,
allowing for determination of 95% CIs and a measure
of heterogeneity.
Results
Initial searches of MEDLINE and Embase produced 869
and 1 436 papers respectively. The results of the litera-
ture search and subsequent inclusions are detailed in
Fig. 1. A reference management application, Mendeley,
was used to organise papers, and identified 766 duplica-
tions. This left a total of 1 539 papers to be included in
the first round of abstract screening.
Papers that lacked original data, such as reviews and
editorials were excluded. Single case reports, or studies
reporting on very few participants that were structured
as case reports, as opposed to considering the popula-
tion as a whole were also excluded. Other studies were
excluded under the ‘lack of relevant data’ criterion
including those where NCC or epilepsy featured briefly
as a component of a much wider study, with few details
regarding their specific diagnosis or assessment. If it was
uncertain from the abstract alone whether or not data
would be relevant to this review, then it was included
for phase 2 evaluation if it met with all further inclusion
criteria. In total, 1 368 papers were excluded in phase 1,
leaving 171 suitable papers for full text review.
All papers in phase 2 were read and critically reviewed.
The greatest proportion of papers excluded in phase 2,
were excluded due to a lack of neuroimaging or autopsy
for the diagnosis of NCC. Many studies either were con-
ducted in locations that were too geographically remote
to practically transport all participants to facilities where
CT or MRI were available, or in areas where this equip-
ment was not available even in such facilities.
Thirty papers were excluded due to the way in which
the diagnosis of epilepsy was ascertained, mainly due to
lack of distinction made between different seizure types,
with no defined guidelines concerning classification. A
number of papers also only investigated participants
who had suffered from a single seizure, with no lifetime
recurrence. In a few cases, papers were excluded because
participants were classified as epileptic based only on
self-reported questionnaire data, with no confirmation
from a clinician. 138 papers in total were excluded in
phase 2, leaving 33 studies for final inclusion in data
extraction and meta-analysis.
The main characteristics of case-control studies that
were included are summarized in Additional file 2, and
for cross-sectional and cohort studies in Additional file 3.
Of 13 included case-control studies, 6 were cross-sectional
in origin, and used screening questionnaires to identify
PWE within whole communities. The remaining studies
generally identified PWE from outpatients in hospitals, or
from those attending epilepsy clinics within the study area.
The majority of individuals within the control groups was
randomly identified from the general population, or was
non-epileptic family members of individuals in the case
groups; the latter has an advantage in that it allows for a
certain degree of genetic matching, whereby the potential
for familial aggregation of NCC or epilepsy susceptibility is
partially controlled for. When controls were taken from
the general population, most studies attempted to match
cases in terms of age, sex and socioeconomic background,
on a 1:1 basis, however this was often not achieved due to
many refusals to participate. In two studies, archived CT
data was used as a control group, as opposed to living
participants; this was justified due to ethical reasons
surrounding the unnecessary risk imposed on healthy
individuals in undergoing CT scanning that was not for
their own benefit.
A total of 13 studies used in the proportion-based
meta-analysis were cross-sectional in design, and a
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further 13 were cohort-based. All cross-sectional studies
identified PWE using screening questionnaires, adminis-
tered either to whole communities, if small enough, or
to random samples of communities if the total popula-
tion was too large to be included in its entirety. 12 out
of 13 cohort studies were hospital-based, 4 of which
reported on paediatric populations alone.
Very few studies explicitly stated exact values for the
number of individuals concluded to have NCC and/or
epilepsy. Regarding NCC, a noticeable amount of studies
reported serological and neuroimaging results independ-
ently with no comment on how certain a diagnosis these
results would constitute. All studies where overall diagnoses
were considered used the Del Brutto diagnostic criteria [30]
to define NCC cases as either probable or definitive (The
Del Brutto criteria include: 1) absolute-histologic demon-
stration of the parasite from biopsy of a brain or spinal cord
lesion, cystic lesions showing the scolex on CT or MRI, and
direct visualization of subretinal parasites by funduscopic
examination; 2) major-lesions highly suggestive of
neurocysticercosis on neuroimaging studies, positive
serum enzyme-linked immuneelectrotransfer blot for
the detection of anticysticercal antibodies, resolution of
intracranial cystic lesions after therapy with albendazole
or praziquantel, and spontaneous resolution of small
single enhancing lesions; 3) minor-lesions compatible with
neurocysticercosis on neuroimaging studies, clinical
manifestations suggestive of neurocysticercosis, positive
CSF enzyme-linked immunosorbent assay for detection
of anticysticercal antibodies or cysticercal antigens, and
cysticercosis outside the CNS; and 4) epidemiologic-
evidence of a household contact with Taenia solium
infection, individuals coming from or living in an area
where cysticercosis is endemic, and history of frequent
travel to disease-endemic areas) [30].
A clear total for individuals diagnosed with epilepsy
was also rarely stated, and had to be inferred. Due to
these factors, a set of guidelines had to be developed
in order to extract data regarding NCC and epilepsy
frequency in a consistent manner.
For determination of epilepsy frequency, ideally ILAE
guidelines would be stated and used to categorize
Fig. 1 Flowchart showing literature search results over the different exclusion phases
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seizure types, of which epileptic seizures would be
one. Where possible, only epilepsy cases defined as
active were included. In the absence of such defined
data sets, individuals in which seizures were described as
recurrent and occurring over a period of more than 24 h
were included in the epilepsy totals.
When deciding which cases to include in the totals for
NCC infection, the Del Brutto criteria [30] were the
preferable referral point, as they were the most consist-
ent set of guidelines used between studies. Where these
criteria were used, both definitive and probable NCC
cases were included in the total. Where these criteria
were not used, NCC cases were defined through the
number of cases in which CT or MRI images indicated
the presence of NCC, whether lesions were compatible
with, suggestive of, or definitive of, NCC. Serological re-
sults in isolation were not considered when determining
NCC frequency, although they could be included when
used in conjunction with the Del Brutto criteria [30].
Risk of developing epilepsy following NCC infection
Case-control data were used to calculate ORs for each
study, with associated 95% CIs and p values. Secka et al.
[31] was excluded despite meeting all inclusion criteria,
as no individuals from either the case or control group
met the criteria for NCC diagnosis; EITB was negative
for all participants, and although 11 individuals tested
positive on Ag-ELISA, no lesions suggestive of NCC
were detected on CT scans. Although these data are use-
ful in suggesting that NCC is not a cause of epilepsy in
the Gambia, where the study was conducted, this ap-
pears to be due to the fact that NCC is very uncommon
in this area, and does not support the more relevant hy-
pothesis that NCC, when present, does not cause epi-
lepsy. The lack of an exposure group does not allow for
the calculation of an associated OR.
Statistical analysis of the remaining 12 case-control
studies is shown in Table 1. A statistically significant
association (p < 0.05) between NCC infection and epi-
lepsy was found in 8 studies, with 2 further studies
approaching statistical significance [32, 33]. ORs ranged
from 2.06 (95% CI: 1.25–3.40) to 6.93 (95% CI: 2.74–
17.51). A statistically significant common OR, estimated
using a random effects model, of 2.76 (95% CI: 2.19–
3.48) was found (Fig. 2). This implies that an individual
who is exposed to NCC infection has an approximately
2.76 times higher risk of developing epilepsy compared
to an individual who is not exposed to NCC infection.
The proportion of PWE with concurrent NCC infec-
tion was highly variable, with a range of 36.59% [33] to
100% [32]. It should be noted that, despite NCC being
defined as the exposure, and epilepsy as the outcome,
both case and control populations were initially defined
through the identification of people with or without epi-
lepsy, and NCC diagnosis was determined secondarily.
This meant that in the majority of studies, the number
of NCC cases, and therefore the size of the exposure
groups, were far smaller than the number of epilepsy
cases, forming the outcome groups. For example, in
Hunter et al., [32] the number of people identified as
having NCC was only 6, all of which had epilepsy, giving
a proportion of 100% and forming the upper boundary
of the proportion range. In contrast, 344 individuals did
not have NCC, forming the control group; these two
populations are so different in size that comparisons are
unlikely to be reliable, which highlights an important
limitation evident in multiple studies included for ana-
lysis. The proportion of controls with epilepsy was only
slightly more consistent, and ranged from 10.62% [34] to
67.05% [35].
The I2 test for heterogeneity gave a value of 0.00%
(95% CI: 0.00–57.84), suggesting a high level of
Table 1 Results from case-control studies investigating the association between NCC exposure and epilepsy
Study PWE with
NCC (n)
PWE without
NCC (n)
PWOE with
NCC (n)
PWOE without
NCC (n)
Odds ratio 95% confidence interval z-Statistic P value
De Oliveira Taveira et al. (2015) [17] 37 82 12 94 3.54 1.73–7.23 3.46 0.0005
Hunter et al. (2015) [32] 6 170 0 174 13.31 0.74–238.02 1.76 0.0786
Mwape et al. (2015) [40] 20 29 7 33 3.25 1.20–8.79 2.323 0.0202
Cherian et al. (2014) [58] 12 68 7 61 1.54 0.57–4.16 0.848 0.3962
Moyano et al. (2014) [35] 109 173 26 85 2.06 1.25–3.40 2.830 0.0046
Singh et al. (2012) [59] 27 79 13 93 2.45 1.18–5.06 2.412 0.0159
Winkler et al. (2009) [60] 38 174 10 188 4.11 1.99–8.49 3.811 0.0001
Prasad et al. (2008) [41] 29 31 31 76 2.29 1.19–4.42 2.479 0.0132
Del Brutto et al. (2005) [61] 5 14 1 18 6.43 0.67–61.47 1.615 0.1062
Montano et al. (2005) [33] 15 24 26 85 2.04 0.94–4.46 1.794 0.0727
Cruz et al. (1999) [34] 14 12 17 101 6.93 2.74–17.51 4.095 <0.0001
Garcia-Noval et al. (1996) [38] 36 40 12 39 2.93 1.33–6.43 2.669 0.0076
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homogeneity between studies, and that differences in
study data were not attributable to variations between
studies.
Proportions of NCC in epileptic populations
A total of 26 studies reporting prevalence rates of epi-
lepsy and NCC contained suitable data for the determin-
ation of proportions of NCC in epileptic populations
(Table 2). Five studies were conducted in Africa, 8 in
Asia (all from India), 12 in South America and 1 in
Central America. In Mwanjali et al. [36], the only PWE
who underwent CT scanning were those who had previ-
ously tested positive on Ag-ELISA, to conserve resources
for those at higher risk of actually having NCC. How-
ever, this meant that out of a total of 123 people identi-
fied as having epilepsy, only 28 had a CT scan; this was
considered sufficiently low to exclude this study from
further statistical analysis. This represents a significant
limitation of this review that was encountered quite
consistently, where even studies that did have access to
neuroimaging tended to rely more strongly on serological
data for NCC diagnosis.
Proportions of NCC cases within epileptic populations
ranged from 10.10% (95% CI: 6.28–15.17) to 56.18%
(45.25–66.68). A common proportion of 31.54% (95%
CI: 26.86–36.41) was estimated using a random effects
model; this value suggests that in a population of indi-
viduals with epilepsy, approximately one-third of them
will have associated NCC infection. However, the I2 test
for heterogeneity was 91.01% (95% CI: 87.98–93.28),
suggesting extremely high variability between studies;
this makes it relatively unlikely that conclusions drawn
from these data will be sufficiently reliable. The forest
plot shown in Fig. 3 depicts these results, and also gives
a visual representation of the degree of heterogeneity
between studies.
There was some variation between proportions when
stratified by continent: the mean proportion of NCC-
associated epilepsy in African studies was 30.93%, 27.02%
in Asian studies, and 36.15% in South American studies.
Although none of these results deviate significantly from
the common mean, it is worth noting that there is a differ-
ence of nearly 10% between Asian and South American
studies, suggesting a relatively substantial difference in
the strength of association between NCC and epilepsy
between these continents. These results therefore sug-
gest a greater proportion of epilepsy cases in South
American countries is associated with NCC compared
to other endemic areas around the world.
Discussion
In total, 33 studies met the criteria for inclusion in both
statistical and qualitative analyses. A significant associ-
ation was found between NCC exposure and epilepsy in
a meta-analysis of these data, with a common OR of
2.76 (95% CI: 2.19–3.48) indicating just under a 3 times
higher risk of developing epilepsy in individuals infected
with NCC compared to those with no NCC infection.
This is a slightly lower value compared to a previous
systematic review by Quet et al. [37], where a common
OR of 3.4 (95% CI: 2.7–4.3) was reported following
meta-analysis of data from studies in Africa only. This
study did not specify neuroimaging as an inclusion cri-
terion, instead relying almost exclusively on serological
data. Considering Brazil and Ecuador [38, 39] have the
highest reported rates of NCC-epilepsy co-morbidity, it
was expected that the inclusion of studies from this con-
tinent would have resulted in a higher common OR
compared to African countries only.
One single case-control study by De Oliveira Taveira
et al. [17] investigated the link between NCC and a spe-
cific type of epilepsy caused by hippocampal sclerosis,
known as mesial temporal lobe epilepsy (MTLE-HS),
Fig. 2 Meta-analysis of case-control studies, showing the individual odds ratios (ORs), with associated Cis
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nested within a study of the association between NCC
and epilepsy in general. Results showed a statistically
significant association between NCC and MTLE-HS,
however when MTLE-HS cases were not included in
further analysis, there was no significant association
found between NCC and other types of epilepsy.
Another interesting observation made by a number of
case-control studies was the high rates of calcified cysti-
cerci in epilepsy, compared to other stages of cyst evolu-
tion, such as viable or transitionary phases. Mwape et al.
[40] reported that the majority of NCC lesions they
identified in PWE were calcified, indicating that seizures
are more likely to develop in the later stages of the dis-
ease. Furthermore, Prasad et al. [41] noted that asymp-
tomatic NCC cases were more likely to display cysts in
the viable stage than in any other stage of NCC develop-
ment. This was to be expected, as it has been suggested
that seizures may be associated with inflammatory re-
sponses generated in response to cyst degeneration,
whereas viable cysts generally remain undetected due to
immune evasion mechanisms [7]. However, despite this
general trend, it has been observed that amongst asymp-
tomatic NCC sufferers there exists substantial variability
in the different stages of cyst development observed
[41], and it is still not certain why some individuals
develop symptoms whilst other with similar pathological
presentations do not.
A common proportion of NCC cases within epileptic
populations of 31.54% (95% CI: 26.86–36.41) was esti-
mated using a random effects model; this value indicates
that within the populations investigated, approximately
one-third of PWE had concurrent NCC infection. This
is in accordance with a previous review by Ndimubanzi et
al [29], which reported a pooled estimate of 29.0% (95%
CI: 22.9–35.5%). Results for I2 tests of heterogeneity,
both in this review and Ndimubanzi et al. [29], were
high: 91.01% (95% CI: 87.98–93.28) and 92.5% (95% CI:
88.1–94.6%) respectively. This highlights a significant
Table 2 Results from cross-sectional and cohort studies, reporting on prevalence rates of NCC and epilepsy respectively in different
populations, with associated proportions
Study Study country Number of PWE Number of people with NCC
(Number who had CT or MRI)
Proportion of NCC
in PWE
95% confidence intervals
Mwape et al. 2015 [40] Zambia 56 20 (49) 40.82 27.00–55.79
Sahu et al. 2014 [39] India 61 23 (61) 37.71 25.61–51.04
Bianchin et al. 2014 [62] Brazil 191 71 (191) 37.17 30.31–44.45
Moyano et al. 2014 [35] Peru 301 109 (282) 38.65 32.94–44.61
Millogo et al. 2012 [42] Burkina Faso 72 20 (68) 29.41 18.98–41.71
Del Brutto and Del Brutto,
2012 [63]
Ecuador 431 120 (431) 27.84 23.66–32.33
Blocher et al. 2011 [64] Tanzania 212 35 (212) 16.51 11.78–22.21
Goel et al. 2011 [65] India 141 49 (141) 34.75 26.94–43.22
Raghava et al. 2010 [66] India 116 39 (101) 38.61 29.09–48.82
Foyaca-Sibat et al. 2009 [23] South Africa 244 34 (92) 36.96 27.12–47.66
Lescano et al. 2009 [9] Peru 42 23 (42) 54.76 38.67–70.15
Rajshekhar et al. 2006 [67] India 194 55 (162) 33.95 26.71–41.80
Velasco et al. 2006 [68] Brazil 512 139 (512) 27.15 23.34–31.22
Singh et al. 2006 [69] India 525 169 (525) 32.19 28.21–36.37
Da Gama et al. 2005 [70] Brazil 89 50 (89) 56.18 45.25–66.68
Nicoletti et al. 2005 [57] Bolivia 124 34 (105) 32.38 23.57–42.21
Montano et al. 2005 [33] Peru 39 15 (39) 38.46 23.36–55.38
Del Brutto et al. 2005 [61] Ecuador 24 5 (19) 26.32 9.15–51.20
Cruz et al. 1999 [34] Ecuador 31 14 (26) 53.85 33.94–76.48
Palacio et al. 1998 [71] Colombia 643 76 (546) 13.92 11.13–17.11
Singhi & Singhi, 1997 [54] India 100 13 (100) 13.00 7.11–21.20
Nair et al. 1997 [72] India 198 20 (198) 10.10 6.28–15.17
Garcia-Noval et al. 1996 [38] Guatemala 76 36 (76) 47.37 35.79–59.16
Arruda et al. 1991 [73] Brazil 210 57 (210) 27.145 21.25–33.69
Gulati et al. 1991 [74] India 170 27 (170) 15.88 10.74–22.26
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amount of between-study variation, which makes it diffi-
cult to draw accurate conclusions from associated data.
This variation can be attributed to a wide variety of
causes, such as differences in study design, use of
hospital-based versus community-based populations,
and of course the substantial differences in community
demographics, such as socioeconomic status, sanitation
infrastructure and agricultural practices.
As in the case-control studies, multiple cohort and
cross-sectional studies, reported a greater proportion of
calcified cysticerci than other phases of cyst develop-
ment in PWE found to have NCC. In accordance with
this finding, the correlation between serology and devel-
opment of epilepsy was further weakened, due to the
fact that serological assays such as EITB only have
adequate sensitivity for viable cysticerci, and for the
most part do not detect calcified cysts [32]. Interestingly,
Millogo et al. [42] found that PWE with NCC were
significantly older than PWE without NCC, and there-
fore hypothesised that the increased proportion of
calcified cysts identified may be associated with a correl-
ation between age and symptomatic NCC. These find-
ings may indicate that seizures develop during the later
stages of NCC development. However, this correlation
has not been sufficiently established, and studies such as
those conducted by Mwape et al. [40] found no such
association between symptomatic NCC and age.
Could a genetic predisposition exist?
It cannot be disputed that there are noticeably high rates
of comorbidity between NCC and epilepsy in certain
areas of the world. While strong evidence to suggest
NCC as a direct cause of epilepsy may be lacking, there
is a link between the two conditions that still remains to
be defined. One hypothesis is that NCC and epilepsy are
indirectly linked by a third factor, which may be genetic
in nature [43]. That the clinical manifestations of NCC
infection may be related to specific genotypes has been
under consideration since it became apparent that cer-
tain individuals of the same age and sex, within similar
populations and with similar pathological findings, can
present with contrasting clinical profiles [33].
One study found a significant association between
symptomatic individuals experiencing seizures and the
expression of MMP-9 polymorphisms leading to in-
creased blood-brain-barrier (BBB) permeability, com-
pared to asymptomatic control subjects [44]. MMP-9 is
an enzyme that has a central role in the degradation
and breakdown of the BBB, and increased expression
may lead to an influx of immune cells that mediate the
inflammatory responses and have been associated with
the degradation of NCC cysticerci, stimulating seizure
activity in affected individuals [44]. This suggests that
the propensity to develop symptoms associated with
NCC may be related to the degree of inflammation
generated in response to parenchymal cysticerci, with
certain genetic polymorphisms playing a role in associ-
ated regulatory pathways. Another study found an asso-
ciation between polymorphisms of the TLR4 gene and
susceptibility to NCC [45]. It has been suggested that
the Th2 branch of the adaptive immune response is
responsible for maintaining an asymptomatic state in
NCC patients, and that a shift from this response to the
Th1 response is a key component of the transition from
asymptomatic infection to the development of symptoms
such as seizures [45]; it was considered a distinct
Fig. 3 Meta-analysis of cross-sectional and cohort studies, showing the individual proportions of NCC in PWE, and associated 95% CIs
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possibility that the polymorphisms identified in this study
may drive this shift from the Th2 to the Th1 response.
This theory of genetic involvement in NCC symptom-
atology is supported by studies reporting familial
aggregation of disease phenotypes within certain regions
[19, 46]. A study in Mexico found that amongst popula-
tions of women who were equally exposed to NCC
infection, children born to mothers with a multi-cyst in-
fection had a significantly higher reported risk of also
developing a multi-cyst infection, compared to children
born to mothers with only single cyst infection, or with
no NCC infection [47], suggesting a genetic role in
susceptibility to infection. NCC pathologies also show a
degree of regional specificity, where localization of the
infection to the subarachnoid space is common in Latin
America, whereas parenchymal infection is far more
prevalent in Asia and Africa [19] which may indicate a
correlation between human genotypes and clinical mani-
festations of the disease. However, other studies report
no discernible association between genotype and devel-
opment of seizures [48].
A potential link with hippocampal sclerosis
NCC may be involved as a component of a complex
pathological pathway that eventually leads to the devel-
opment of epilepsy, without directly causing individual
seizure events. For example, it has been observed that
in NCC-endemic countries, there are frequently high
rates of individuals diagnosed with mesial temporal
lobe epilepsy associated with hippocampal sclerosis
(MTLE-HS) who are subsequently found to have a con-
current NCC infection [49]; this could represent a path-
way precipitated by NCC infection, in which hippocampal
sclerosis functions as an intermediate step in the indirect
development of epilepsy. Initial precipitating injuries (IPIs)
such as cranial trauma, neonatal hypoxia, and certain
infections have already been well documented as indir-
ectly causing temporal lobe epilepsy through hippo-
campal insult and subsequent sclerosis [50]; it is not
inconceivable that a neuroparasitic disease such as
NCC could function in a similar way.
The mechanisms behind this hypothetical relationship
may either be directly caused by the physical presence of
cysticerci within the hippocampal region, leading to
inflammation-mediated pathology, or indirectly by the
damage and consequent synaptic reorganization caused
by repetitive provoked seizures [51]. NCC would func-
tion as an IPI in this situation by initially causing pro-
voked symptomatic seizures, but initiating longer-term
epileptogenic pathology whereby unprovoked epileptic
activity would persist even following the removal of
NCC as a stimulus.
Although issues similar to those encountered when asses-
sing the causal nature of the NCC-epilepsy relationship are
also present when considering a link with hippocampal
sclerosis, a number of studies have reported results that
support this theory. Bianchin et al. [52] found that 42.85%
of individuals presented with a single parenchymal NCC
lesion that was directly associated with the physiological
location of MTLE-HS, suggesting an anatomical relation-
ship between the two conditions; this indicates reasonable
evidence to refute the possibility of coincidental comorbid-
ity. De Oliveira Taveira et al. [17], found a statistically sig-
nificant association between NCC and epilepsy only when
cases of MTLE-HS were included in the meta-analysis,
however when these cases were excluded, there was no as-
sociation found between NCC and other types of epilepsy.
Data from studies investigating the link between NCC and
epilepsy could appear to clearly show a significant associ-
ation between the two, but with a different underlying link
existing, that connects them, indirectly. Other studies indi-
cate a coincidental relationship only between NCC and
MTLE-HS [53], probably due to high prevalence rates of
both conditions in certain endemic countries.
Despite trying to avoid the major limitations encoun-
tered by previous studies and reviews, there were some
issues that occurred consistently throughout the study
selection and analysis processes. Population sizes were
often initially very large, where substantial proportions
of certain communities were screened for the presence
of either NCC or epilepsy, but the study would identify
only very small numbers of individuals who were afflicted
with either condition, therefore being relevant to the in-
vestigation. Data sets for a number of studies were much
smaller than anticipated, which led to greater heterogen-
eity between papers. It was also very difficult to avoid
study selection bias in terms of the actual populations that
were sampled, since in order to identify a great enough
number of individuals with NCC to make the study
worthwhile, endemic populations, often of a very particu-
lar type, were specifically chosen. For example, a large
number of studies sampled pig farming communities only,
however by doing so, significant selection bias is intro-
duced, and the studies cannot be extrapolated to the
general population. The use of hospital-based studies,
as opposed to community-based studies may also have
introduced selection bias.
Despite applying strict exclusion criteria regarding the
use of neuroimaging, the majority of included studies, all
with access to CT or MRI, tended to rely far more heav-
ily on serological data for the diagnosis of NCC (see ref-
erences in Tables 1 and 2). While this is more practical
in rural communities in endemic countries, this can lead
to significant overestimations of the number of individ-
uals with active NCC infection. Several studies had a
limited number of CT scans available to them due to
financial restrictions, so these would only be carried out
as confirmatory tests on random samples of serologically
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positive individuals, or would only be used on those
deemed at highest risk of having the infection. Neuroim-
aging is generally considered a more reliable diagnostic
technique than serological assays, as NCC infection can
be directly visualised within the brain, and cysts can be
accurately localised to specific areas. Ideally, all study
subjects would receive some form of neuroimaging,
results from which would form the most substantial evi-
dence for the diagnosis of NCC, with serology serving
only as further confirmation.
However, despite the emphasis placed on the benefit
of using neuroimaging it must be noted that they also
have flaws that may have led to the misclassification of
NCC cases in some studies. Although certain aspects of
a lesion identified through neuroimaging may display
features that strongly indicate an NCC infection, such as
an identifiable scolex [30], lesions that are not so clearly
defined could be attributed to other infectious causes,
such as tuberculosis (TB), or, rarely, tumours or micro-
abscesses [54]. TB is difficult to distinguish from NCC,
especially in countries where there are very high preva-
lence rates of both diseases [55]. Although guidelines are
available to help differentiate TB and NCC when asses-
sing results from CT or MRI, they are not infallible [55].
Administration of the Mantoux test and chest X-rays
may help to exclude TB as a differential diagnosis in
study participants [56], but this approach was not
adopted by the majority of studies and it cannot be
certain that all lesions identified as NCC were not of a
different pathological origin.
Finally, there was a dearth of studies reporting inci-
dence, as opposed to prevalence data. A major issue with
using epilepsy prevalence data is that there is no way of
determining whether NCC (as exposure), occurred before
or after the development of epilepsy, the proposed out-
come [57]. This makes it very difficult to assess whether
or not the epilepsy was caused by the NCC, or whether it
was a pre-existing condition. The ideal design for a study
assessing causality would be a prospective study in which
a cohort of newly-diagnosed NCC sufferers are followed
up over a number of years to see how many subsequently
develop epilepsy.
Conclusion
While our results from this review concur with previous
investigations in concluding that NCC does increase the
risk of developing epilepsy, and has a reasonably high
prevalence in populations of PWE in certain endemic
countries, and it cannot be disputed that there are high
rates of comorbidity in certain populations, existing
available data are not sufficient to determine the exist-
ence of a causal association between NCC and epilepsy.
To understand the complex interplay between these two
conditions, a number of changes to the way in which
research in this area is carried out need to be imple-
mented. Study designs should be prospective in nature
to accurately determine epilepsy incidence in cohorts of
NCC sufferers, so that it can be clearly stated that epi-
lepsy is an outcome of NCC, and does not represent a
pre-existing condition due to high prevalence rates of
both diseases in endemic countries. In addition to this, a
universal set of diagnostic criteria, such as those pro-
posed by Del Brutto et al. [30], should be consistently
implemented across all studies, so that accurate compar-
isons can be made between data collected in the major-
ity of studies worldwide. Improvements to future studies
will also depend directly on the increased availability of
resources such as CT and MRI in developing endemic
countries. In the absence of reliable estimates of its
global burden, NCC will remain of low priority in the
eyes of funding agencies - a truly neglected disease.
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